Natco Pharma Lenalidomide Capsules secures USFDA okay
Hyderabad: Pharma major, Natco Pharma Limited, announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5mg, 10mg, 15mg, and 25mg strengths, from the U.S. Food and Drug Administration (USFDA), and the tentative approval of the 2.5mg and 20mg strengths. NATCO, along with its marketing partner Arrow International Limited (a U.S. affiliate...
Hyderabad: Pharma major, Natco Pharma Limited, announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5mg, 10mg, 15mg, and 25mg strengths, from the U.S. Food and Drug Administration (USFDA), and the tentative approval of the 2.5mg and 20mg strengths.
NATCO, along with its marketing partner Arrow International Limited (a U.S. affiliate of Teva Pharmaceutical Industries Ltd), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name REVLIMID.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Read also: Natco Pharma enters agreement with Eli Lilly for COVID drug Baricitinib
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd